Australia markets open in 6 hours 5 minutes

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.56000.0000 (0.00%)
As of 9:55AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.5600
Open1.5600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.5600 - 1.5600
52-week range1.5600 - 1.6500
Volume5,000
Avg. volume174
Market cap50.58M
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
    GlobeNewswire

    Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

    IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022 Geneva, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has extended its research collaboration agreement with Indivior PLC (LON: INDV). As part of the extension, Indi

  • Addex Therapeutics to Present at Access to Giving Virtual Conference  on July 14, 2021
    GlobeNewswire

    Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

    Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addex’s clinical trial program. The conference is free to all registrants. Registration DetailsDate: W

  • Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
    GlobeNewswire

    Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

    Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery toolsAddex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in preclinical development for neurocognitive disorders Geneva, Switzerland, July 1, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug dis